3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
13
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
17
Head and Neck Neoplasms
10
Melanoma
9
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
6
Neoplasm Metastasis
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Ovarian Neoplasms
4
Mouth Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Laryngeal Neoplasms
3
Colonic Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma
2
Interventions
pembrolizumab
29
Paclitaxel
7
Magnetic Resonance Spectroscopy
7
Cisplatin
7
Pemetrexed
6
Docetaxel
6
Carboplatin
6
Standard of Care
5
Radiotherapy
5
Nivolumab
5
Drug Therapy
5
Specimen Handling
4
Gemcitabine
4
Cetuximab
4
Blood Specimen Collection
4
epacadostat
3
X-Rays
3
Surveys and Questionnaires
3
Practice Guidelines as Topic
3
Oncolytic Virotherapy
3
Nicotine
3
Fluorouracil
3
Filgrastim
3
Cyclophosphamide
3
Bupropion
3
Bortezomib
3
Biopsy
3
spartalizumab
2
selpercatinib
2
sargramostim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
cemiplimab
×
Head & Neck
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled